http://seekingalpha.com/article/47821-cytogen-the-wall-street-analyst-forum-presentation-transcript?....
Partial Quote:
"In terms of the market opportunity for CAPHOSOL, we believe that the market opportunity is approximately $250 million. If you look at the estimated new cases of cancer every year, the percentage that undergo chemotherapy, the number of treatment cycles, the fact that there will be four to ten doses per day and the fact that approximately 40% of all patients will develop oral mucositis. So, this comes up with a market potential of about $250 million and that’s based upon using most of the factors on the left end of the range here, if you use the right end, I think the potential market opportunity could be significantly greater."
Recent CYTO News
- Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 • GlobeNewswire Inc. • 09/20/2024 01:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/19/2024 08:17:07 PM
- Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering • GlobeNewswire Inc. • 09/19/2024 08:01:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 09/18/2024 08:19:22 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/18/2024 04:15:12 AM
- Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering • GlobeNewswire Inc. • 09/17/2024 09:00:00 PM
- Form F-1/A - Registration statement for certain foreign private issuers: [Amend] • Edgar (US Regulatory) • 09/16/2024 05:55:02 PM
- Form F-1/A - Registration statement for certain foreign private issuers: [Amend] • Edgar (US Regulatory) • 09/16/2024 01:29:34 PM
- Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia • GlobeNewswire Inc. • 09/16/2024 12:30:00 PM
- Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11 • GlobeNewswire Inc. • 09/03/2024 01:01:00 PM
- Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark • GlobeNewswire Inc. • 08/23/2024 01:01:00 PM
- Form F-1 - Registration statement for certain foreign private issuers • Edgar (US Regulatory) • 08/22/2024 08:53:27 PM
- Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances • GlobeNewswire Inc. • 08/16/2024 01:01:00 PM
- Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models • GlobeNewswire Inc. • 08/12/2024 01:02:00 PM
- Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles • GlobeNewswire Inc. • 07/19/2024 01:01:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 07/08/2024 09:17:01 PM
- Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management • GlobeNewswire Inc. • 06/20/2024 01:01:00 PM
- Altamira Therapeutics Provides Business Update • GlobeNewswire Inc. • 05/28/2024 02:31:08 PM
- Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal • GlobeNewswire Inc. • 05/23/2024 12:47:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/16/2024 08:15:32 PM
- Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation • GlobeNewswire Inc. • 05/01/2024 12:47:00 PM
- Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal • GlobeNewswire Inc. • 04/24/2024 12:47:00 PM
- Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024 • GlobeNewswire Inc. • 04/04/2024 12:45:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM